Abstracts tagged "Hydroxychloroquine"

Abstract Number: 0875 • ACR Convergence 2021
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Shivani Garg¹, Karen Hansen², Betty Chewning¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…
Abstract Number: 0989 • ACR Convergence 2021
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users
April Jorge¹, Ronald Melles², Carol Conell³, Na Lu⁴, Michael Marmor⁵, Lucy Young⁶, Natalie McCormick¹, Yuqing Zhang⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Redwood City Medical Center, Department of Ophthalmology, Kaiser Permanente Northern California, Redwood City, CA, ³Kaiser Permanente Northern California, Palo Alto, CA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts Eye and Ear Institute, Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases; however, the known risk factors for HCQ retinopathy (its major…
Abstract Number: 1163 • ACR Convergence 2021
Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence
Shivani Garg¹, Betty Chewning¹, Noah Kaitz¹, Shelby Gomez¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of SLE therapy as it improves damage-free survival in all SLE patients. Yet, in new users, as few as…
Abstract Number: 1462 • ACR Convergence 2021
Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares
April Jorge¹, Christian Mancini¹, Xiaoqing Fu¹, Gary Ho², Yuqing Zhang³, Karen Costenbader⁴ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²New York University, New York, NY, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA, ⁵Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is an important treatment for systemic lupus erythematosus (SLE), known to reduce disease activity and flares. To minimize the risk of toxicity,…
Abstract Number: 1705 • ACR Convergence 2021
The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users
Marco Gianpiero Antivalle¹, Michele Agosti¹, Giuliana La Paglia², Alberto Batticciotto³, Maria Chiara Ditto⁴, SIMONE PARISI⁵ and Piercarlo Sarzi-Puttini⁶, ¹L. Sacco University Hospital, Milano, Italy, ²L.Sacco University Hospital, Milano, Lombardia, Italy, ³Ospedale di Circolo - Fondazione Macchi, Varese, Lombardia, Italy, ⁴AOU Città della Salute e della Scienza, Torino, Italy, ⁵AOU Città della Salute e della Scienza, TURIN, Italy, ⁶L.Sacco University Hospital, Milano, Italy
Background/Purpose: Hydroxychloroquine (HCQ) has been used safely for over 60 years in rheumatic patients. However, following its recent use in covid-19 disease, its safety has…
Abstract Number: 1743 • ACR Convergence 2021
Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity
Mayce Haj-Ali¹ and H. Michael Belmont², ¹NYU Grossman School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). There is limited data assessing cardiac toxicity as arrhythmias…
Abstract Number: 1753 • ACR Convergence 2021
Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors
Laurence Magder¹, Michelle Petri² and Daniel Goldman², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In SLE, treatment with hydroxychloroquine (HCQ) has been shown to be associated with reduced SLE flares and reduced risk of damage in several different…
Abstract Number: 1764 • ACR Convergence 2021
Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients
Kelley Brady, Roberta Alexander, Rory Bloch, Mark Rudolph, Karina Baggiani, Deborah Stimson and Anja Kammensheidt, Exagen Inc., Vista, CA
Background/Purpose: HCQ is an antimalarial drug effective in the treatment of rheumatologic conditions. High blood levels, advanced age, and extended treatment duration are associated with…
Abstract Number: 1768 • ACR Convergence 2021
Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus Erythematosus with Stable Disease Activity
Risa Wakiya¹, Kiyo Ueeda¹, Hiromi Shimada¹, Shusaku Nakashima¹, Mikiya Kato¹, Taichi Miyagi², Mansour mai¹, Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹, Tomohiro Kameda¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: In systemic lupus erythematosus (SLE), atherosclerosis is strongly associated with vital prognosis. On the other hand, arteriosclerosis is strongly influenced by serum adipokines. The…
Abstract Number: 322 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Leanna Wise¹, Stavros Savvas ² and Elizabeth Ortiz ², ¹LAC+USC/Keck Medicine of USC, Los Angeles, CA, ²LAC+USC/Keck Medicine of USC, Los Angeles
Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…
Abstract Number: 2579 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity
Eric Liu¹ and Andras Perl ², ¹SUNY Upstate University Medical Center, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in our field of work with retinal toxicity being a known possible long-term side effect of the…
Abstract Number: 896 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
April Jorge¹, Na Lu ², Hyon K. Choi ¹, John Esdaile ³, Diane Lacaille ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE and is often used in the treatment of RA. Use of HCQ has been associated…
Abstract Number: 2581 • 2019 ACR/ARP Annual Meeting
Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus
Nicolle Medina-Cintrón¹, Ileana Vázquez-Otero ¹, Mariangelí Arroyo-Ávila ¹, Lorena González-Sepúlveda ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hydroxychloroquine (HCQ) is one of the main drugs used for the treatment of systemic lupus erythematosus (SLE). Nonetheless, HCQ-induced retinal toxicity remains a major…
Abstract Number: 1130 • 2019 ACR/ARP Annual Meeting
The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine
Abdulrahman Alrashid¹, Millicent Anne Stone ², Nigel Davies ² and David D'Cruz ³, ¹King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia, ²Guy's and St Thomas Foundation Trust, London, United Kingdom, ³The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom
Background/Purpose: Background: Hydroxychloroquine (HCQ) is widely used in treatment of autoimmune rhuematological diseases. In particular, systemic lupus erythermatosus where it proved to prevent disease flare, reduce…
Abstract Number: 2829 • 2019 ACR/ARP Annual Meeting
Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk
Shivani Garg¹, Betty Chewning ², Karen Hansen ³, Beth Martin ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW - School of Pharmacy, Madison, Madison, ³UW Madison, Madison
Background/Purpose: Up to 83% of patients with SLE are nonadherent to hydroxychloroquine (HCQ) which results in a 36% higher risk of renal failure, and 8-fold…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].